MIXTURE AND PHARMACEUTICAL COMPOSITION COMPRISING Z-4-HYDROXYTAMOXIFEN AND CYCLODEXTRIN

Abstract: The invention concerns a mixture and a pharmaceutical composition consisting of or comprising Z-4-hydroxy-tamoxifen and at least one cyclodextrin.

Description: Mixture and pharmaceutical composition comprising Z-4-hydroxytamoxifen and cyclodextrin Field of the invention The present invention relates to new pharmaceutical compositions of Z-4-hydroxytamoxifen having improved solubility and stability. Background of the invention 4-hydroxytamoxifen [l-(p-β-dimethylaminoethoxyphenyl)-l-(p-hydroxyphenyl)-2-phenylbut-l- en ] is a metabolite of tamoxifen, a well known cytostatic antiestrogen. Tamoxifen, a nonsteroidal antiestrogen, is primarily used for the treatment of hormone dependent breast cancer. Special tests have shown, that 4-hydroxytamoxifen is more potent in treating breast cancer than tamoxifen ( Jordan V.C. et al.; J. Endocr. (1977), 75, 305-316). There exist two isomers of 4-hydroxytamoxifen, the Z- and E-isomer. The Z-isomer is the active component for treating breast cancer but the stability of this isomer is very low. The Z-E-isomerization of 4- hydroxytamoxifen takes place primarily in solution and an equilibrium of the two isomers is reached after a short time. The E-isomer shows estrogen activity and this activity is a contrast to the Z-isomer. For the treatment of breast cancer the content of the E-isomer has to be less than one percent to guarantee a successful treatment. A further problem of Z-4-hydroxytamoxifen is its poor aqueous solubility. To get a solution for an injection, the 4-hydroxytamoxifen has to be soluble in an aqueous medium. Therefore it exists a strong need for parenteral formulations of the anticancer antiestrogens. Injectable high concentration 4-hydroxytamoxifen formulations will have important clinical benefit 1) in the attempt to reach high concentrations in tissue. This is necessary especially when combinations of 4-hydoxytamoxifen with cytotoxic drugs are given to a patient. High plasma concentrations are more effective in reversing multidrug resistance than low concentrations. An injectable formulation enables high peak concentrations in blood and tissues without exposing the patient to long-term treatment; 2) when given locally into a tumor . This enables a high and efficacious concentration in the tumor to be achieved. DE 28 07 599 discloses the use of 4-hydroxytamoxifen for the treatment of breast cancer. EP 0 287 690 discloses the stabilization of the Z-isomer of 4-hydroxytamoxifen by forming an adduct with a solvent. This process of stabilization is very time consuming and complicated. The preferred solvents forming the adduct are acetone, butanone, acetylacetone, mesityloxide, acetic acid ethylester and acetoacetic acid ethylester. These adducts are not suitable for parenteral administration. EP 0 616 529 discloses parenteral preparations of antineoplastic agents like tamoxifen, toremifen, desmethyltamoxifen or desmethyltoremifen in form of stable emulsions or liposomes to ensure improved solubility. The problem of a stable solution of Z-4-hydroxytamoxifen with a E-isomer content of less than one percent and an easy and cheap process of stabilization and the possibility of solubiiization of a therapeutic effective amount of Z-4-hydroxytamoxifen in an aqueous solution has not been solved until now. Summary of the invention Main object of the present invention is to provide new compositions of Z-4-hydroxytamoxifen with improved stability and aqueous solubility. It has now surprisingly been found, that Z-4-hydroxytamoxifen can be stabilized by complexation with cyclodextrin. It has further been found that the solubility of the Z-4- hydroxytamoxifen in aqueous solution can be improved by forming a Z-4-hydroxytamoxifen/ cyclodextrin complex. Therefore it is now possible to produce special dosage forms containing the Z-4-hydroxytamoxifen/ cyclodextrin complex, resulting from the improved solubility and stability. Thus, the invention concerns a mixture consisting of or comprising Z-4-hydroxy tamoxifen and cyclodextrin. According to the invention Z-4-hydroxytamoxifen may be used per se or as a pharmaceutically acceptable salt thereof, such as hydrochloride, sulfate, phosphate, acetate, tartrate or citrate. The cyclodextrin may be a pharmaceutically acceptable cyclodextrin or a cyclodextrin which is used for pharmaceutical preparations. Thus, the cyclodextrin may be at least one component selected from the group consisting of gamma-cyclodextrin, β-cyclodextrin, dimethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, random methylated β-cyclodextrin and maltosyl-β-cyclodextrin. Especially, the cyclodextrin is gamma-cyclodextrin. Further, the mixture according to the invention may comprise or contain cyclodextrin in such an amount that the stability and solubilty of Z-4-hydroxy tamoxifen in aqueous media is improved. Further, the mixture according to the invention may have a molar ratio of Z-4-hydroxytamoxifen to cyclodextrin within the range of 1 : 1 to 1 : 50, preferably 1 : 1 to 1 : 20 and especially 1 : 1 to 1 : 10. Further, the mixture according to the invention may be obtainable by - dissolving or suspending Z-4-hydroxytamoxifen and cyclodextrin in a liquid medium and - bringing the solution or suspension to dryness. The liquid medium may be an aqueous medium and especially water. Further, the liquid medium may be subjected to ultrasonification during said dissolving or suspending or thereafter. Further, the resulting solution or suspension may be filtrated before bringing it to dryness, especially filtrated through a membrane filter of an average pore size of about 0.45 x lO -0" m or less. Further, the resulting optionally ultrasonicated and optionally filtrated solution or suspension may be chilled, the resulting precipitate separated and the separated precipitate brought to dryness. Further, the invention concerns a pharmaceutical composition comprising or consisting of a mixture according to the invention and optional auxiliary agents. The pharmaceutical composition according to the invention may be tailored for an administration selected from the group consisting of parenteral, oral, rectal, transdermal and ophthalmic administration. Especially, the pharmaceutical preparation according to the invention may be tailored for parenteral administration. Thus, the pharmaceutical preparation according to the invention may comprise or consist of a solution or suspension of a mixture according to the invention in an aqueous medium. According to a preferred embodiment, the aqueous medium is water or physiological saline. Thus, the problem underlying the invention is solved by a pharmaceutical composition comprising or consisting of ■ Z-4-hydroxytamoxifen as active ingredient and as excipients ■ at least one cyclodextrin. As regards auxiliary agents to be used for the preparation of compositions according to the invention, reference can be made to the state of the art such as DE 28 07 599, EP 0287 690 or EP 0 616 529. In order to describe the invention more specifically but without intending to limit the scope of the invention in any way the following examples are presented: Example 1; 50 mg (0.129 mmol) 4-hydroxytamoxifen (MW 387.5) and 1,0 g (0.771 mmol) γ-cyclodextrin (MW 1297) were dissolved in 35 ml physiological saline (phosphat buffer pH 7). An opalescent solution was obtained by ultrasonication for about 5 minutes. The content of 4- hydroxy tamoxifen in the solution was 5%. After filtration through a 0,45 μm membrane filter the clear filtrate was chilled by a dry ice/ ethanol mix and the complex was isolated by freeze drying. The 4-hydroxytamoxifen content of the complex is 3,33 % ± 0,1 % by weight. Example 2: 155,2 mg 4-hydroxy tamoxifen/ γ-cyclodextrin complex according to example 1 were dissolved in 50 ml distilled water. A clear solution was immediately obtained. The pH value of the solution was around pH 7,1. The solution was filtered through a 0,22 μm membrane filter. The solution was filled in flasks. The samples were stored for eight days under sterile conditions at room temperature (25 °C ) and at 4 °C. The content of the solution was determined by diluting the solution five times with 50 % ethanol and then analyzed spectrometrically. The 4- hydroxytamoxifen content of the standard (25 °C and no storage time ) was 98-5 μg/ ml. The content of 4-hydroxytamoxifen was 98,1 μg/ ml at 25 °C after eight days of storage. After eight days of storage at 4 °C the content of 4-hydroxytamoxifen was 98,5 μg/ ml. Example 3: A stability test was performed for 24 hours at room temperature. The 4-hydroxytamoxifen/ γ-cyclodextrin complex according to example 1 was dissolved in water and exposed to day light at room temperature. The E/Z iso er ratio was analyzed by capillary electrophoresis (CE). The results are shown in table 1. The amount of the E-isomer was below the detection limit demonstrating the stabilizing effect of the cyclodextrin complex in solution. Table 1: ♦ calculation based on a 5-point calibration, n=2 Example 4: A 10-day stability test in water and in 96 % ethanol at room temperature and exposure to normal day light, using 4-hydroxytamoxifen and the 4-hydroxytamoxifen/ γ-cyclodextrin complex prepared according to example 1 was performed. The change of E/Z isomer ratio was analyzed with capillary electrophoresis. The results are shown in table 2. Table 2: Calculated isomer ratios during 10-days storage Sample In water Ratio r e/z Efficiency value* 4-Hydroxytamoxifen n. a. ** 0,223 4,65 4-Hydroxytamoxifen/ 0 0,048 γ-cyclodextrin complex * ratio of uncomplexec and c omplexed 4-hydrc )xytamoxifen r e z values ** n.a. - not applicable, it is not soluble in water The 4-hydroxy tamoxifen/ γ-cyclodextrin complex dissolved in water showed no detectable change in isomer ratio (r e/z = 0). In the tested samples no detectable amount of E isomer was found. A small change of isomer ratio (r e z = 0,048) was found using 96 % ethanol as solvent for the 4- hydroxy tamoxifen/ γ-cyclodextrin complex. 4-Hydroxytamoxifen dissolved in 96 % ethanol showed a considerable change in isomer ratio (r e/z = 0,223). The change of isomer ratio in water was not investigated due to the insolubility of 4- hydroxytamoxifen in water. Example 5: A twelve months stability test of the solid complex according to example 1 was performed under controlled conditions (25 °C, 60 % relative humidity (R. H. )) and a control sample in the refrigerator (4 °C, no controlled humidity). The E/Z isomer ratio was analyzed by capillary electrophoresis. The results are shown in table 3. Table 3: *E isomer not detectable ** not measured

Claims: Patent Claims 1. Mixture comprising or consisting of Z-4-hydroxytamoxifen and at least one cyclodextrin. 2. Mixture according to claim 1, wherein the cyclodextrin is a pharmaceutically acceptable cyclodextrin or a cyclodextrin which is used for pharmaceutical preparations. 3. Mixture according to claim 1 or 2, wherein the cyclodextrin is at least one component selected from the group consisting of gamma-cyclodextrin, β-cyclodextrin, dimethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, random methylated β-cyclodextrin and maltosyl-β-cyclodextrin. 4. Mixture according to claim 3, wherein the cyclodextrin is gamma-cyclodextrin. 5. Mixture according to any of the preceding claims, wherein the mixture comprises or contains cyclodextrin in such an amount that the stability and solubilty of Z-4-hydroxytamoxifen in aqueous media is improved. 6. Mixture according to any of the preceding claims and especially claim 5, wherein the molar ratio of Z-4-hydroxytamoxifen to cyclodextrin is within the range of 1 : 1 to 1 : 50, preferably 1 : 1 to 1 : 20 and especially 1 : 1 to 1 : 10. 7. Mixture according to any of the preceding claims, wherein the mixture is obtainable by - dissolving or suspending Z-4-hydroxytamoxifen and cyclodextrin in a liquid medium and - bringing the solution or suspension to dryness. 8. Mixture according to claim 7, wherein the liquid medium is an aqueous medium and especially water. 9. Mixture according to claim 7 or 8, wherein the liquid medium is subjected to ultrasonification during said dissolving or suspending or thereafter. 10. Mixture according to any of claims 7 to 9, wherein the resulting solution or suspension is filtrated before bringing it to dryness, especially filtrated through a membrane filter of an average pore size of about 0.45 x 10"° " m or less. 11. Mixture according to any of claims 7 to 10, wherein the resulting optionally ultrasonicated and optionally filtrated solution or suspension is chilled, the resulting precipitate is separated and the separated precipitate is brought to dryness. 12. Pharmaceutical composition comprising or consisting of a mixture according to any of the preceding claims, optional auxiliary agents and optionally at least one additional active ingredient. 13. Pharmaceutical composition according to claim 12 tailored for an administration selected from the group consisting of parenteral, oral, rectal, transdermal and ophthalmic administration. 14. Pharmaceutical composition according to claim 13, wherein the preparation is tailored for parenteral administration. 15. Pharmaceutical composition according to claim 14, wherein the preparation comprises or consists of a solution or suspension of a mixture according to any of claims 1 to 11 in an aqueous medium. 16. Pharmaceutical composition according to claim 15, wherein the aqueous medium is water or physiological saline.

Inventors: FISCHER WILFRIED, KLOKKERS KARIN, SENDL-LANG ANNA, FISCHER, WILFRIED, KLOKKERS, KARIN, SENDL-LANG, ANNA
Applicants: FISCHER WILFRIED, HEXAL AG, KLOKKERS KARIN, SENDL LANG ANNA, FISCHER, WILFRIED, KLOKKERS, KARIN, SENDL-LANG, ANNA
Application year: 1998
Main classification: A61K31
IPC codes: A61K31, A61K47, A61P35